Trial Profile
Phase 1a Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of AKB 4924 in Healthy Male Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Jul 2020
Price :
$35
*
At a glance
- Drugs GB 004 (Primary)
- Indications Inflammatory bowel diseases
- Focus Adverse reactions
- Sponsors Aerpio Therapeutics
- 19 May 2020 Results published in Gasteroenterology in conjunction with Digestive Disease Week 2020
- 15 Mar 2017 Status changed from active, no longer recruiting to completed.
- 17 Jan 2017 Status changed from recruiting to active, no longer recruiting.